Table 1. Patients’ Characteristics (n = 437).
|
Characteristics
|
Number (%) | |
|---|---|---|
| Male | 204 (46.7) | |
| Mean age (range) | 64 y (51–74 y) | |
| Mean age at the asthma onset (range) | 46 y (26–59 y) | |
| Atopic asthma | 267 (61.1) | |
| Smoking status | Non-smoker | 260 (59.5) |
| Ex-smoker | 146 (33.4) | |
| Current smoker | 31 (7.1) | |
| Co-morbidity | Allergic rhinitis | 216 (49.5) |
| Sinusitis | 127 (29.0) | |
| Hypertension | 114 (26.0) | |
| Atopic dermatitis | 60 (13.6) | |
| COPD | 49 (11.3) | |
| Heart diseases | 46 (10.5) | |
| DM | 40 (9.1) | |
| AIA | 27 (6.1) | |
| ABPA | 11 (2.6) | |
| CSS | 8 (1.8) | |
| Drug treatment | ICS | 407 (93.2) |
| SFC (Adoair®) | 138 (31.6) | |
| BUD (Pulmicort®) | 134 (30.7) | |
| FP (Flutide®) | 102 (23.3) | |
| HFA-BDP (Qvar®) | 24 (5.5) | |
| CIC-BDP (Alvesco®) | 9 (2.1) | |
| Systemic steroid | 41 (9.4) | |
| LABA | 290 (66.4) | |
| Oral β2 stimulant | 7 (1.6) | |
| Stick β2 stimulant | 27 (6.2) | |
| Theophylline | 138 (31.6) | |
| LTRA | 111 (25.4) | |
| Control | Total control (ACT 25) | 120 (27.5) |
| Well control (ACT 20-24) | 210 (48.1) | |
| Poor control (ACT <20) | 107 (24.5) | |
| GINA treatment step | 1 | 24 (5.5) |
| 2 | 76 (17.4) | |
| 3 | 33 (7.6) | |
| 4 | 263 (60.2) | |
| 5 | 41 (9.4) | |
DM: Diabetes mellitus; AIA: Aspirin-induced asthma; ABPA: Allergic bronchopulmonary aspergillosis; CSS: Churg–Strauss syndrome; ICS: inhaled corticosteroid; SFC: salmeterol/fluticasone propionate combination; BUD: budesonide; FP: fluticasone propionate; HFA: hydrofluoroalkane; BDP: beclomethasone dipropionate; CIC: ciclesonide; LTRA: leukotriene receptor antagonist